ARCHIVES

Will Latest Report By Rosenberg Stir Up Critics? Some DCT Board Members Defend the Press

This article is from The Cancer Letter archive.

Vol. 13 No. 15 | April 10, 1987

Download PDF Visit The Full Archive

Related Articles

FDA Approves BMS’s Yervoy For Metastatic Melanoma

March 25, 2011

In Brief: Hatch Bill Would Require NDA Sponsors To Pay Fee; IND, Generic Drug NDAs Would Be Exempt

August 22, 1986

NCI Support Crucial for Israel cancer Studies; Weizmann Top Recipient

June 17, 1977

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

January 8, 1993

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

ASCO Strategic Plan Seeks To Increase Value to Members, Public

May 24, 2002